| ��������PD-L1/PD-1���������ƶ��Ժ�ɫ�����½�չ |
| |
| 引用本文： | ¹��ӡ,�����.��������PD-L1/PD-1���������ƶ��Ժ�ɫ�����½�չ[J].中国药学杂志,2015,50(22):1931-1935. |
| |
| 作者姓名： | ¹��ӡ ����� |
| |
| 作者单位： | ????????????????о???,???? 250012 |
| |
| 摘 要： |
|
| 关 键 词： | ??????? ???????? ????????????????-1??????? ????????????????-1??????? |
Advance Development of Immunotherapy on Malignant Melanoma with Targeting Inhibition of PD-L1/PD-1 |
| |
| LU Yu-yin,GUO Xiu-li.Advance Development of Immunotherapy on Malignant Melanoma with Targeting Inhibition of PD-L1/PD-1[J].Chinese Pharmaceutical Journal,2015,50(22):1931-1935. |
| |
| Authors: | LU Yu-yin GUO Xiu-li |
| |
| Affiliation: | Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China |
| |
| Abstract: | ??Malignant melanoma presents a significant therapeutic challenge to clinicians with characteristics of early metastasis, rapid development, poor prognosis and high mortality. Many therapies for metastatic melanoma are limited by these characteristics. With the development of immunotherapy mechanism for malignant melanoma, a large number of antibody agents for the treatment of malignant melanoma entered the clinical trials. To our great delight, the new drugs of pembrolizumab and nivolumab have been approved by FDA in 2014 after successfully passing phase ?? clinical trial, which bring a chance of survival to patients with unresectable or metastatic advance melanoma. This review briefly discusses recent development and advances of anti-PD-L1/PD-1 antibody drugs against melanoma. |
| |
| Keywords: | |
|
| 点击此处可从《中国药学杂志》浏览原始摘要信息 |
|
点击此处可从《中国药学杂志》下载全文 |
|
